The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
In this study, perioperative propranolol β-blockade was administered to patients with surgically resectable primary gastrointestinal tumors to explore the safety, efficacy, and alleviation of perioperative psychological stress. At the same time, a multi-omics study was conducted using clinical samples to explore the activation of anti-tumor immune response and its mechanism.
Eligibility Criteria
Inclusion Criteria: 1. Surgically resectable primary gastric cancer and colorectal cancer; 2. Age greater than 18 years old and less than 65 years old; 3. Negative pregnancy test for women of childbearing age; 4. ECOG score ≤2; 5. Signed informed consent. 6. Resting blood pressure greater than 100/60mmHg, heart rate greater than 60 beats per minute. Exclusion Criteria： 1\) Pregnant or breastfeeding women, or women with pregnancy plans within six months; 2) Patients with absolute or relative contraindications to propranolol: 1. Pathological sinus node syndrome; 2. Sinus bradycardia (less than 60 beats/minute); 3. First, second or third degree AV block; 4. Resting blood pressure less than 100/60 mmHg; 5. untreated pheochromocytoma; 6. untreated thyroid disease; 7. Patients on dihydropyridine or non-dihydropyridine calcium channel blockers (e.g., diltiazem, verapamil, nifedipine, amlodipine); 8. Severe peripheral vascular disease (intermittent claudication); 9. Patients on antiarrhythmic